After accounting for the anticipated biodistribution for an mAb from plasma to lung tissue, simulations in adult subjects suggested that 4 mg/kg Q2W would largely achieve Ctrough values in lung that exceed the IC50 that demonstrated reduction in granuloma growth in the in vitro sarcoidosis model (granuloma area fraction IC50 = 5.197 μg/mL; IL-1β IC50 = 3.465 μg/mL); whereas doses of 2 mg/kg Q2W or Q4W or 4 mg/kg Q4W would fall below the in vitro IC50 (Figure 5). This evidence concerns the gene IL1B and sarcoidosis.